Genetic and Inflammatory Markers in Cardiovascular Disease (GEM) Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

21 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-01-31

Study Completion Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an investigator initiated registry aimed at assembling a blood/serum and genomic resource (bank) of human blood samples with accompanying clinical data mainly from patients who are scheduled to undergo cardiac catheterization at UC Davis Medical Center, but may also include other eligible individuals. Funding is from institutional/divisional research funds.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inflammatory Genomics in Human Carotid Artery Disease

NCT00070668

Cardiovascular Diseases Atherosclerosis Carotid Artery Diseases +1 more

COMPLETED

Genetic Variants and Regulation of Specialized Pro-resolving Mediator

NCT04698291

Healthy Inflammatory Disease Cardiovascular Diseases

RECRUITING

Multi-Analyte, Genetic, and Thrombogenic Markers of Atherosclerosis

NCT01276678

Coronary Artery Disease

UNKNOWN

Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study

NCT00262691

Healthy Coronary Disease Myocardial Infarction +1 more

UNKNOWN

Cardiogenomics Registry

NCT00861575

Cardiovascular Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is aimed at assembling a blood/serum and genomic resource (bank) of human samples with accompanying clinical data mainly from patients who are scheduled to undergo cardiac catheterization at UC Davis Medical Center, but may also include other eligible individuals. These samples will be analyzed at UC Davis Medical Center for determination of biomarker levels, and concomitantly analyzed at UC San Francisco in an IRB-approved protocol at that institution for genetic analysis (UCSF IRB approval # for this study is H711-15138-03; protocol name is "Discovery of Gene Mutations and Polymorphisms that Contribute to the Risk of Atherosclerosis"; principal investigator is John P. Kane, MD). All samples sent to UCSF will be de-identified and catalogued using an alphanumeric code. A number of candidate genes will be studied to detect mutations and polymorphisms that could contribute to the risk of atherosclerosis. The technique of hybridization sequencing will be employed for this. The techniques of classical statistical genetics will be employed for both cosegregation analysis and for the genome search approach. Clinical follow-up may be obtained at 6 and 12 months.